Mezzion Pharma Co.Ltd
Mezzion Pharma Co.,Ltd. engages in the development, licensing, and commercialization of drugs for the treatment of vascular diseases. It is developing Udenafil, a PDE5 inhibitor to treat erectile dysfunction, benign prostatic hyperplasia, pulmonary arterial hypertension, overactive bladder, hepatic portal hypertension, and chronic obstructive pulmonary diseases. The company was formerly known as … Read more
Mezzion Pharma Co.Ltd - Asset Resilience Ratio
Mezzion Pharma Co.Ltd (140410) has an Asset Resilience Ratio of 13.09% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Mezzion Pharma Co.Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Mezzion Pharma Co.Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩11.50 Billion | 13.09% |
| Total Liquid Assets | ₩11.50 Billion | 13.09% |
Asset Resilience Insights
- Moderate Liquidity: Mezzion Pharma Co.Ltd has 13.09% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Mezzion Pharma Co.Ltd Industry Peers by Asset Resilience Ratio
Compare Mezzion Pharma Co.Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AGP Ltd
KAR:AGP |
Pharmaceuticals | 0.71% |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250 |
Pharmaceuticals | 4.82% |
|
DongKoo Bio&Pharma Co. Ltd
KQ:006620 |
Pharmaceuticals | 4.28% |
|
NatureCell Co.Ltd
KQ:007390 |
Pharmaceuticals | 0.00% |
|
Sam-A Pharm. Co. Ltd
KQ:009300 |
Pharmaceuticals | 34.37% |
|
Kyung Dong Pharmaceutical Co. Ltd
KQ:011040 |
Pharmaceuticals | 5.22% |
|
WooGene B&G Co. Ltd
KQ:018620 |
Pharmaceuticals | 3.35% |
|
Oscotec Inc
KQ:039200 |
Pharmaceuticals | 61.00% |
Annual Asset Resilience Ratio for Mezzion Pharma Co.Ltd (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Mezzion Pharma Co.Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 38.67% | ₩28.62 Billion | ₩74.00 Billion | -24.54pp |
| 2023-12-31 | 63.21% | ₩58.25 Billion | ₩92.15 Billion | +3.24pp |
| 2022-12-31 | 59.97% | ₩32.40 Billion | ₩54.02 Billion | +3.73pp |
| 2021-12-31 | 56.24% | ₩47.21 Billion | ₩83.93 Billion | -8.68pp |
| 2020-12-31 | 64.93% | ₩49.10 Billion | ₩75.63 Billion | -4.98pp |
| 2019-12-31 | 69.91% | ₩41.16 Billion | ₩58.87 Billion | -0.18pp |
| 2018-12-31 | 70.09% | ₩52.61 Billion | ₩75.06 Billion | +0.23pp |
| 2017-12-31 | 69.86% | ₩51.72 Billion | ₩74.04 Billion | +3.08pp |
| 2016-12-31 | 66.77% | ₩64.04 Billion | ₩95.90 Billion | +44.36pp |
| 2015-12-31 | 22.42% | ₩23.10 Billion | ₩103.05 Billion | -- |